BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Authors » Alfred Romann

Alfred Romann

Articles

ARTICLES

Chairman, investors join in going-private bid for Wuxi valued at $3.2B

May 6, 2015
By Shannon Ellis and Alfred Romann
HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman.
Read More

Asia in the Spotlight: Chairman, investors join in going-private bid for Wuxi valued at $3.2B

May 5, 2015
By Shannon Ellis and Alfred Romann

Chairman, investors join in going-private bid for Wuxi valued at $3.2B

May 4, 2015
By Shannon Ellis and Alfred Romann
HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman.
Read More

Asia in the Spotlight: APACMed launched to give Asia Pacific med-tech companies a voice

April 29, 2015
By Alfred Romann

Med-tech stocks enjoy bullish times in Hong Kong and Shanghai after reforms

April 14, 2015
By Alfred Romann

Hutchison's fruquintinib advances to late-stage colorectal cancer trial

April 1, 2015
By Alfred Romann
HONG KONG – Calling success in the first proof-of-concept trial for its cancer drug, fruquintinib, Hong Kong-based Hutchison Medipharma said the drug achieved primary efficacy endpoints.
Read More

Hutchison's fruquintinib advances to late-stage colorectal cancer trial

April 1, 2015
By Alfred Romann
HONG KONG – Calling success in the first proof-of-concept trial for its cancer drug, fruquintinib, Hong Kong-based Hutchison Medipharma said the drug achieved primary efficacy endpoints. Phase III trials will now start for the colorectal indication of fruquintinib, even as development continues in two other indications.
Read More

Asia in the Spotlight: With China sizzling, Cook Medical looks to VIP markets for expansion

March 11, 2015
By Alfred Romann

Singapore leads Southeast Asia's effort to rev up innovative drug development

March 4, 2015
By Alfred Romann
TAIPEI, Taiwan – Companies across Southeast Asia are taking multiple steps to develop or attract more innovation and power their biotechnology industries.
Read More

Singapore leads Southeast Asia's effort to rev up innovative drug development

March 3, 2015
By Alfred Romann
TAIPEI, Taiwan – Companies across Southeast Asia are taking multiple steps to develop or attract more innovation and power their biotechnology industries.
Read More
View All Articles by Alfred Romann

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing